G1 Therapeutics (NASDAQ:GTHX) Receives “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research report sent to investors on Tuesday morning, The Fly reports. The brokerage currently has a $82.00 price objective on the stock, up from their previous price objective of $72.00.
GTHX has been the topic of several other reports. Cowen reissued a buy rating on shares of G1 Therapeutics in a research note on Thursday, December 12th. BTIG Research increased their target price on shares of G1 Therapeutics from $51.00 to $80.00 and gave the stock a buy rating in a research note on Tuesday, January 7th. ValuEngine upgraded shares of G1 Therapeutics from a sell rating to a hold rating in a report on Friday, December 27th. BidaskClub downgraded shares of G1 Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 8th. Finally, Zacks Investment Research lowered shares of G1 Therapeutics from a hold rating to a sell rating in a report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $61.43.
Shares of NASDAQ GTHX traded down $0.25 during midday trading on Tuesday, reaching $24.45. The stock had a trading volume of 2,063 shares, compared to its average volume of 233,561. The firm has a market cap of $953.07 million, a price-to-earnings ratio of -8.20 and a beta of 2.23. G1 Therapeutics has a twelve month low of $13.87 and a twelve month high of $41.80. The company has a debt-to-equity ratio of 0.03, a quick ratio of 14.28 and a current ratio of 14.28. The company’s 50 day moving average price is $25.83 and its 200 day moving average price is $27.25.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of Montreal Can lifted its position in G1 Therapeutics by 93,600.0% in the 2nd quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock valued at $86,000 after acquiring an additional 2,808 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in G1 Therapeutics by 18.8% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,166 shares of the company’s stock worth $97,000 after acquiring an additional 500 shares during the last quarter. Hodges Capital Management Inc. purchased a new position in G1 Therapeutics during the 2nd quarter worth $235,000. Metropolitan Life Insurance Co NY lifted its position in shares of G1 Therapeutics by 51.3% during the third quarter. Metropolitan Life Insurance Co NY now owns 11,600 shares of the company’s stock valued at $264,000 after purchasing an additional 3,935 shares in the last quarter. Finally, Parametric Portfolio Associates LLC purchased a new position in G1 Therapeutics during the second quarter worth about $406,000. Institutional investors own 77.25% of the company’s stock.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Featured Article: Roth IRA
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.